Joseph Tucker, PhD, CEO of Enveric Biosciences, Naples, FL, discusses the potential of psychedelics to treat mental health issues such as depression and anxiety in cancer patients. These mental health issues can lead to poorer outcomes for patients, as well as greatly decreasing quality of life, so creating effective treatments is vital. Dr Tucker discusses how Enveric Biosciences is working on the early pre-clinical development of a novel variant of psilocybin.
This video presentation contains forward-looking statements and forward-looking information within the meaning of applicable securities laws. Actual results could differ materially from those contemplated by the forward-looking statements as a result of certain factors. A discussion of these factors, including risks and uncertainties with respect to Enveric, is set forth in Enveric’s filings with the Securities and Exchange Commission (SEC), including the Company’s Annual Report on Form 10-K and its Quarterly Reports on Form 10-Q.